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Abstract 
Neuropsychiatric (NP) involvement is a prevalent and often severe feature of Systemic 
Lupus Erythematosus (SLE). Diverse factors are involved in its aetiopathogenesis and 
treating this condition is often quite challenging. However, clinical trials of biologic 
therapies in patients with SLE exclude those with severe NP manifestations. The place for 
the use of biologic approaches is thus even more problematic than it is for other aspects of 
SLE. Here we review the current evidence for the use of biologic therapies in the treatment 
of NPSLE.  
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Introduction 
The last two decades have seen a revolution in the treatment of patients with more 
common autoimmune rheumatic diseases notably rheumatoid arthritis, psoriatic arthritis 
and ankylosing spondylitis with the successful introduction of a range of biologic therapies. 
Targeting the molecules and cells which evidence suggests are likely to be involved in the 
aetiopathogenesis of these diseases has been a major advance [1]. Although these drugs are 
not a panacea, and infection, particularly during the first three months of treatment, remains 
an issue with some of the biologic drugs (notably those that block TNF-alpha) [2], the 
overwhelming benefit to hundreds of thousands of patients around the world is undeniable.  
In contrast, the introduction of biologic therapies for the more sinister autoimmune 
rheumatic conditions vasculitis and, notably, systemic lupus erythematosus (SLE) has been 
far less compelling. Only one drug, Belimumab, which blocks a B-cell activating factor 
(BAFF) known as BAFF/BLyS, has been approved by the Federal Drug Administration in 
America and the European Medicines Association for the treatment of lupus and to date is 
restricted to those patients who have skin and joint involvement [3]. Many of the other 
drugs that have been tried, notably Rituximab [4] (which blocks the CD20 molecule on B-
cells); Abatacept [5] (which blocks the interaction between antigen presenting cells and T-
cells); Tabalumab [6] (anti-BLys) and Rontalizumab [7] (anti-interferon (IFN) α) have 
failed to meet their primary endpoints in large-scale international trials (although 
Tabalumab did in fact meet its endpoint in one such clinical trial). 
Post-hoc analyses have offered some encouragement in the trials of the above 
agents. For example, in the Rituximab trials, data have indicated that there was a 
serological and a limited clinical response [8]. There has also been a widespread 
recognition that Rituximab does help patients with lupus, but that the poor drug trial design, 
which, notably, allowed the use of far too high a dose of concomitant glucocorticoids 
and/or immunosuppressive drugs, strongly mitigated against any chance that Rituximab 
might have had of showing benefit. Paradoxically, although Rontalizumab did not meet its 
primary endpoints, Silfalimumab, with the same target, did achieve this [9]. 
The majority of companies, when setting up clinical trials in lupus, invariably 
design two sorts of clinical trials. One type focuses on renal disease which has “hard” 
endpoints such as a protein/creatinine ratio, serum creatinine and glomerular filtration rate, 
while the other type of trial focuses on non-renal lupus. Both types of trial, however, make 
a point of excluding patients with significant central nervous system (CNS) lupus. As a 
consequence, there have been no clinical trials at all of patients with this challenging aspect 
of the disease. 
However, CNS disease may occur in up to half of lupus patients [10]. We felt it 
would be useful to review, critically, those publications describing the use of biologics in 
NPSLE. 
Neuropsychiatric SLE 
Lupus is often thought of as a disease with diverse manifestations and nowhere is 
this truer than in the central nervous system. Virtually anything from “migraine to 
madness” may be a feature of central nervous system involvement in SLE. Although the 
American College of Rheumatology (ACR) classification criteria [11] list only seizures and 
psychosis as CNS lupus features, a working party set up by the ACR proposed a set of 
twelve CNS manifestations and seven peripheral nervous system (PNS) manifestations 
which they felt captured the full range of neurological possibilities [12]. 
In 2012, Borowoy and colleagues reported the prevalence of neuropsychiatric SLE 
(NPSLE) in 1253 adult patients of a multicenter Canadian cohort according to four 
different definitions. Using the ACR classification criteria it was 6.4%, but higher the less 
strict the definition (up to 38.6% when including manifestations included in ACR, SLAM, 
SLEDAI or SLICC indices) [13]. 
Figure 1 indicates the contributory factors linked to the cause of CNS lupus 
manifestations. In many cases no single aetiopathogenic mechanism is responsible. Rather 
the diversity of CNS features reflects the complex potential combination of factors 
indicated in the figure. This topic has been reviewed in detail recently [14]. 
True cerebral vasculitis has been found rarely in brain biopsies during life but was 
also reported in 10% of cases at post-mortem [15]. In the past twenty years it has 
increasingly been recognised that thrombotic change linked to the presence of 
antiphospholipid antibodies, including anti-β2 Glycoprotein 1, is a major potential cause of 
involvement of the CNS in lupus [16]. Lupus patients may thus suffer strokes relatively 
early in life, occasionally being a presenting feature of the disease.  
A cross-reaction between antibodies to double-stranded DNA and the N-methyl-D-
aspartate (NMDA) receptor might be an important contributory factor to particular clinical 
features [17]. The NMDA receptors, although widely distributed throughout the brain, are 
localised within glutamatergic synapses in the amygdala and hippocampus. These sub-
regions are linked to cognitive functions such as emotional processes and memory, 
respectively. An important point linked to this cross-reacting antibody (and others) is that 
the antibodies need to penetrate the blood/brain barrier (or to be produced intrathecally) 
before they can cause genuine pathology.  
The role of anti-ribosomal P antibodies is controversial [18]. The frequency with 
which these antibodies are found is varied in lupus populations. Probably, in most of them, 
it is about 15-20%, perhaps higher in some ethnic groups. The initial suggestion that their 
presence in the serum of lupus patients was strongly associated with depression and 
psychosis in SLE patients [19] has not been universally accepted, although levels in the 
spinal fluid are likely to be more relevant to clinical manifestations than serum levels. 
The capacity of cytokines and chemokines to promote intrathecal antibody 
production to manipulate neurotransmitter release and recruit immune cells [14] strongly 
implicates (at least some of) these molecules in the development of NPSLE.  
The presence of IL-6 in the cerebrospinal fluid has been noted [20], although more 
recent studies have focused on the TNF-related weak inducer of apoptosis (TWEAK) [21]. 
There are some data to suggest that stress is able to induce an increase in the 
production of nitric oxide (NO) in the brain via the iNOS pathway [22]. It is believed that 
inflammatory cytokine components, immune complexes and even antiphospholipid 
antibodies have an effect on this pathway, which has been reported to be active in patients 
with NPSLE.  
Various intrathecal markers of NPSLE have been identified. These include the 
chemokine ligand known as CXCL10, RANTES, FRACTALKINE, the plasminogen 
activator inhibitor 1 and matrix metalloproteinase 9 [14]. 
Biologic drugs in the treatment of NPSLE 
Methods 
We performed a literature search in Medline database, using combinations of the 
following terms: Lupus, Neuropsychiatric, Rituximab, Epratuzumab, Belimumab, 
Tabalumab, Atacicept, Abatacept, Sifalimumab and Rontalizumab. We were looking for 
publications of randomized controlled trials (RCTs), observational studies and case reports 
of adult patients with NPSLE treated with biologic drugs, published in English, French, 
German, Spanish and Portuguese. After excluding articles that were not relevant or that 
contained duplicated data, we identified 16 articles. 
Results and discussion 
Most studies reporting the use of biologic drugs in SLE show their results using a 
global disease activity score and do not present the outcome in specific organ systems. 
However, some studies do assess the efficacy of these therapies in NPSLE, notably 15 
studies with Rituximab and one with Belimumab. We could not find any data about the use 
of other B-cell targeting therapies (apart from Rituximab and Belimumab) or IFNα targeted 
therapies, namely Sifalimumab and Rontalizumab, in NPSLE. 
Belimumab 
Belimumab is currently the only specific targeted drug approved for the treatment of 
SLE, having shown efficacy in two phase III clinical trials [3, 23]. Some observational 
studies have subsequently been published, reporting the “real-life experience” with this 
drug [24-26]. However, as patients with severe neuropsychiatric manifestations were 
excluded from the clinical trials and the observational studies, there is currently little 
evidence about the use of Belimumab in NPSLE. 
In a post-hoc analysis of the BLISS-52 and BLISS-76 trials, which included 1684 
patients with moderately to severely active (SELENA-SLEDAI≥6) seropositive SLE, 
Manzi and collaborators have looked for changes in BILAG and SELENA-SLEDAI organ 
domain scores at week 52 of follow up [27]. They found 45 patients with CNS involvement 
at baseline. The most common manifestation was headache (present in 24 patients) which 
showed a very good response to Belimumab. The improvement rates reported were 20.0%, 
100% and 69.2% with placebo and Belimumab 1 and 10 mg/kg, respectively. 
In addition, 21 patients had neuropsychiatric involvement with a BILAG score A or 
B at baseline. Among those, improvement rates (improvement being defined as a step down 
from an A or B score to a B, C or D score) were, paradoxically, 83.3%, 75.0% and 42.9% 
for placebo (total n=6), Belimumab 1 mg/Kg (total n=8) and 10 mg/Kg (total n=7), 
respectively. These results are somewhat surprising, given the apparent efficacy of the 
placebo in treating patients with NPSLE scoring A or B in BILAG. Caution is needed, 
however, in the interpretation of this results, as the sample size was very small. Information 
about the specific NPSLE features treated was not provided. 
The authors also calculated the worsening rates for BILAG organ domains 
(worsening was defined as a step up from an E, D, C or B score to a B or A score) and for 
SELENA–SLEDAI organ domains (worsening was defined as a positive score shift). In the 
CNS, the rates of worsening s assessed by BILAG, for patients without any A score at 
baseline, were 0.7% (4/562) for placebo, 0.5% (3/556) for Belimumab 1 mg/Kg, and 1.1% 
(6/562) for Belimumab 10 mg/Kg. Considering SELENA-SLEDAI, for patients with no 
involvement at baseline, the rates of worsening were 0.4% (2/551) for placebo, 0.6% 
(3/544) for Belimumab 1 mg/Kg, and 0.4% (2/544) for Belimumab 10 mg/Kg. 
This study has, however, some limitations, as these trials were not designed or 
powered to demonstrate the efficacy of Belimumab in individual organ domains. 
Wallace and colleagues pooled data from the phase II and phase III trials of 
Belimumab, focusing on its safety profile [28]. Psychiatric adverse events were reported 
more frequently with Belimumab treatment than with placebo (12.4% of patients receiving 
placebo and 16.0%, 22.5% and 15.9% of patients receiving Belimumab 1, 4 and 10 mg, 
respectively). The most frequent were depression, insomnia and anxiety. Furthermore, there 
was an approximate two-fold greater risk of developing a psychiatric disorder during the 
study if the patient had a medical history of psychiatric condition, depression, anxiety, or 
insomnia. This was not the case verified with other central nervous system medical history. 
The safety concerns may, therefore, restrict the use of Belimumab in patients with 
psychiatric SLE. 
Rituximab 
Rituximab is a chimeric anti-CD20 antibody that directly targets B cells. It 
eliminates B cells through a variety of mechanisms, notably antibody-dependent cellular 
cytotoxicity, complement-dependent cytotoxicity and apoptosis [29]. 
This monoclonal antibody has been widely used in the treatment of SLE. Most 
publications have described open studies and many successes have been claimed [30, 31]. 
Unfortunately, in the two major clinical trials of Rituximab, one in renal lupus (LUNAR) 
[8] and one in non-renal lupus (EXPLORER) [32], the primary endpoints were not met, as 
discussed previously. 
In respect of NPSLE, we found eight retrospective observational studies, two open 
clinical trials, four small case series and case reports and one systematic review of case 
reports and case series assessing the efficacy of Rituximab (Table 1). Most studies report 
the use of this B-cell depleting drug in refractory cases of NPSLE; the only exception is the 
open trial published by Ye and colleagues [33], conducted in patients with recent onset 
myelopathy, using Rituximab as the first line therapy. The study reported by Abud-
Mendoza and collaborators [34] described six patients treated with Rituximab, however, 
two of them were less than 18 years old and in another patient the CNS manifestation 
reported was an haemorragic stroke, so these three patients were excluded from our 
analysis. 
In Table 2 we have combined data from the 15 studies and show the efficacy of 
Rituximab for each NPSLE manifestation. Overall, these results are very encouraging, 
showing high response rates. The worst results are seen in patients with demyelinating 
syndrome (most cases reported neuromyelitis optica) and in patients with mood disorder, 
although in this case it is difficult to be sure that the mood disorder (often depression) is a 
true NPSLE feature and not a comorbility. 
Conclusion 
With such a diversity of factors contributing to the aetiopathogenesis of NPSLE 
manifestations, it may seem overly optimistic to find a single effective targeted therapy. 
However, the encouraging results reported with the use of Rituximab may prove otherwise. 
A large RCT of Rituximab in NPSLE patients would be important to demonstrate 
compelling evidence of its efficacy. 
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Figure 1: Contributing factors to NPSLE manifestations. 
NMDA: N-methyl-D-aspartate; APA: anti-phospholipid antibody; MMP: Matrix 
Metalloproteinase 1; PAI: plasminogen activator inhibitor 
  
Table 1: Studies assessing the efficacy of Rituximab in adult patients with NPSLE 
Reference 
Type of 
study 
N NPSLE features, n 
Feature 
respons
e (CR) % 
Global 
respons
e (CR) % 
Narváez et 
al, 2011 
[35] 
Systematic 
review of 
case reports 
and case 
series 
35 
Seizures, 6 
Psychosis, 5 
Myelopathy, 5 
Acute confusional state, 6  
Mood disorder, 3 
Demyelinating syndrome,3 
CNS vasculitis, 2 
Headache, 2 
Not specified, 3 
100 
(100) 
100 (60) 
100 (40) 
60 (0)* 
33 (0) 
67 (33) 
100 
(100) 
100(50) 
100 (67) 
85 (50) 
Vital et al, 
2011 [36] 
Retrospectiv
e 
observational 
study 
13 Not specified 92 
Pinto et al, 
2011 [37] 
Retrospectiv
e 
observational 
study 
12 
Myelopathy, 4 
Polineuropathy, 4 
Seizures, 1 
Demyelinating syndrome, 1 
Not specified, 2 
100 
100 
100 
0 
0 
75 
Fernandez- Retrospectiv 11 Not specified 73 
Nebro et al, 
2012 [38] 
e 
observational 
study 
Iaccarino et 
al, 2015 
[39] 
Retrospectiv
e 
observational 
study 
9 
CNS vasculitis, 4 
Seizures, 2 
Psychosis, 1 
Headache, 1 
Cognitive dysfunction, 1 
100 (50) 
100 
(100) 
100 (0) 
0 
100 
(100) 
89 (56) 
Ye et al, 
2011 [33] 
Open clinical 
trial 
6 Myelopathy, 6 83 (67) 
Ramos-
Casals et al, 
2010 [40] 
Retrospectiv
e 
observational 
study 
6 Not specified 80 
Abud-
Mendoza et 
al, 2009 
[34] 
Open clinical 
trial 
3 
Myelopathy, 2 
Movement disorder, 1 
100 
Hickman et 
al, 2015 
[41] 
Retrospectiv
e 
observational 
study 
4 Not specified 100 (25) 
Reynolds et 
al, 2009 
[42] 
Retrospectiv
e 
observational 
4 
Myelopathy, 1 
Seizures, 1 
100 
study Psychosis, 1 
Polineuropathy, 1 
Chehab et 
al, 2007 
[43] 
Case series 3 
Myelopathy, 2 
CNS vasculitis, 1 
100 
Braun-
Moscovici 
et al, 2013 
[44] 
Case report 1 
Demyelinating 
polyradiculoneuropathy 
CR 
Sanz et al, 
2012 [45] 
Case report 1 
Demyelinating 
polyradiculoneuropathy 
PR 
Lateef et al, 
2010 [46] 
Retrospectiv
e 
observational 
study 
1 Not specified CR 
Mok et al, 
2008 [47] 
Case report 1 Demyelinating syndrome NR 
*One patient lost to follow up was excluded from the analysis 
N: number of patients; CR: complete response; PR: partial response; NR: non-responder 
  
Table 2: Efficacy of Rituximab for each NPSLE manifestation 
NPSLE Feature N Response (%) 
CNS 
Myelopathy 20 19/20 (95) 
Seizures 10 10/10 (100) 
Psychosis 7 7/7 (100) 
CNS vasculitis 7 7/7 (100) 
Acute confusional state 6 3/5* (60) 
Demyelinating syndrome 5 2/5 (40) 
Mood disorder 3 1/3 (33) 
Headache 3 2/3 (67) 
Cognitive dysfunction 1 1/1 (100) 
Movement disorder 1 1/1 (100) 
Total 63 53/62 (85) 
PNS 
Polyneuropathy 5 5/5 (100) 
Demyelinating 
polyradiculoneuropathy 
2 2/2 (100) 
Total 7 7/7 (100) 
Not specified 40 33/40 (83) 
Total  110 93/109 (85) 
*One patient lost to follow up was excluded from the analysis 
